U.S. markets closed
  • S&P 500

    3,351.60
    +53.14 (+1.61%)
     
  • Dow 30

    27,584.06
    +410.10 (+1.51%)
     
  • Nasdaq

    11,117.53
    +203.96 (+1.87%)
     
  • Russell 2000

    1,510.34
    +35.43 (+2.40%)
     
  • Crude Oil

    40.59
    -0.01 (-0.02%)
     
  • Gold

    1,885.10
    +2.80 (+0.15%)
     
  • Silver

    23.80
    +0.19 (+0.81%)
     
  • EUR/USD

    1.1670
    +0.0035 (+0.30%)
     
  • 10-Yr Bond

    0.6630
    +0.0040 (+0.61%)
     
  • GBP/USD

    1.2842
    +0.0097 (+0.76%)
     
  • USD/JPY

    105.5280
    -0.0180 (-0.02%)
     
  • BTC-USD

    10,896.93
    +118.12 (+1.10%)
     
  • CMC Crypto 200

    224.73
    +0.81 (+0.36%)
     
  • FTSE 100

    5,927.93
    +85.26 (+1.46%)
     
  • Nikkei 225

    23,511.62
    +307.00 (+1.32%)
     

Here's What CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shareholder Ownership Structure Looks Like

Simply Wall St

A look at the shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.

CASI Pharmaceuticals is a smaller company with a market capitalization of US$242m, so it may still be flying under the radar of many institutional investors. Taking a look at our data on the ownership groups (below), it's seems that institutional investors have bought into the company. We can zoom in on the different ownership groups, to learn more about CASI Pharmaceuticals.

View our latest analysis for CASI Pharmaceuticals

NasdaqCM:CASI Ownership Breakdown July 9th 2020
NasdaqCM:CASI Ownership Breakdown July 9th 2020

What Does The Institutional Ownership Tell Us About CASI Pharmaceuticals?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that CASI Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone, since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at CASI Pharmaceuticals's earnings history, below. Of course, the future is what really matters.

NasdaqCM:CASI Earnings and Revenue Growth July 9th 2020
NasdaqCM:CASI Earnings and Revenue Growth July 9th 2020

Hedge funds don't have many shares in CASI Pharmaceuticals. Looking at our data, we can see that the largest shareholder is IDG Capital Partners with 20% of shares outstanding. In comparison, the second and third largest shareholders hold about 10.0% and 9.0% of the stock. Additionally, the company's CEO Wei-Wu He directly holds 1.9% of the total shares outstanding.

On looking further, we found that 50% of the shares are owned by the top 5 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of CASI Pharmaceuticals

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We can see that insiders own shares in CASI Pharmaceuticals, Inc.. As individuals, the insiders collectively own US$21m worth of the US$242m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

General Public Ownership

The general public holds a 32% stake in CASI. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With a stake of 27%, private equity firms could influence the CASI board. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Private Company Ownership

It seems that Private Companies own 9.0%, of the CASI stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Public Company Ownership

Public companies currently own 10.0% of CASI stock. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks, for example - CASI Pharmaceuticals has 4 warning signs (and 1 which is a bit unpleasant) we think you should know about.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.